Last updated 2026-07-26
- Raised $11.9M grant led by European Innovation Council's Accelerator program, Jul 2024
Total raised
$11.9M
Last: Grant 2024-07
Stage
Pre-Funding
Founded
1996
Headcount
40
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences
About
ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy. This minimally invasive drug-device combination is designed for the selective ablation of unresectable solid tumors. The VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment, leading to immediate occlusion of the tumor blood supply, immunogenic cell death, and immune activation with minimal effect on surrounding healthy tissues. The company holds exclusive rights from the Weizmann Institute of Science (Israel) and Memorial Sloan Kettering Cancer Center (New York) to develop and commercialize drugs and related technologies used in VTP.
Funding history · 1 round · $11.9M total
2024-07
Grant
$11.9M
★ European Innovation Council's Accelerator program
Headcount over time
From 36 (2024-03) to 41 (2026-03) · +5 (+14%) · 6 points · source: Finder history + radar grounding
Q&A
- What is ImPact Biotech's primary focus?
- ImPact Biotech is a clinical-stage biotechnology company developing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy for the selective ablation of unresectable solid tumors.
- When was ImPact Biotech founded?
- ImPact Biotech was founded in January 1996.
- What was ImPact Biotech's most recent funding event?
- In July 2024, ImPact Biotech received a Grant of $2.7 million from the European Innovation Council.
- What is the current employee count for ImPact Biotech?
- ImPact Biotech has 40 employees, falling within the 11-50 employee bucket.
- What was a significant regulatory milestone for ImPact Biotech in late 2023?
- In December 2023, ImPact Biotech received FDA clearance of its IND application for Padeliporfin VTP in pancreatic cancer.
- What is the status of ImPact Biotech's Phase 3 ENLIGHTED clinical trial?
- In September 2024, ImPact Biotech announced 50% enrollment in its Phase 3 ENLIGHTED clinical trial of Padeliporfin VTP in low-grade upper tract urothelial cancer.
- Which institutions granted ImPact Biotech exclusive rights for its VTP technology?
- ImPact Biotech holds exclusive rights from the Weizmann Institute of Science (Israel) and Memorial Sloan Kettering Cancer Center (New York) to develop and commercialize drugs and related technologies used in VTP.
- What was a key collaboration for ImPact Biotech in 2023?
- In August 2023, ImPact Biotech collaborated with Maastricht University to advance Padeliporfin VTP research for pathological myopia.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
biotechnologyoncologycancer-therapypharmaceuticalsimmunotherapycancerminimally-invasive
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | impactbiotech.com/ |
|---|---|
| linkedin.com/company/71243727 | |
| Wikidata | wikidata.org/wiki/Q140045373 |
Identifiers & details
| Legal name | IMPACT BIOTECH LTD |
|---|---|
| Former names | Steba Biotech |
| Founded | 1996-1 |
| Employees (exact) | 40 |
| Wikidata QID | Q140045373 |
Radar intelligence
Patents
| EPO | 5 |
|---|
Web history (Wayback)
| Domain | impactbiotech.com |
|---|
Wikidata
| QID | Q140045373 |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513381319 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2003-02-13 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | אינשטיין 16 נס ציונה |